POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER: CLINICAL INSIGHTS AND REAL-WORLD ANALYSIS AT A SPECIALIZED CENTER IN NORTHEASTERN BRAZIL
DOI:
https://doi.org/10.46765/2675-374X.2025v6n1p258Abstract
Post-Transplant Lymphoproliferative Disorders (PTLD) comprise a heterogeneous group of lymphoid or plasmacytic neoplasms with highly variable presentations, occurring in the setting of immunosuppression following transplantation. Epstein-Barr virus (EBV)-positive PTLD accounts for 60–80% of cases. Due to the rarity of the disease, no phase 3 clinical trials have been conducted to establish standardized treatment protocols, making its management particularly challenging. Objective: to characterize the profile of patients diagnosed with PTLD following kidney, liver, or hematopoietic stem cell transplantation at a specialized center in Northeastern Brazil. Methodology: a retrospective, observational, and single-center cohort study based on medical record analysis. Results: The analysis of the frequency of PTLD by transplanted organ group showed 3.7 cases per 1000 hematopoietic stem cell transplants, 7.0 cases per 1000 kidney transplants and 7.5 cases per 1000 liver transplants. The mean survival time for all patients was 438 days. Patients who achieved complete response had a better overall survival (OS) of 87.5% at 1 year, while those who did not achieve complete response had an OS of 22.2% at 1 year (p=0.00012).
Conclusion: PTLD is commonly an aggressive disease with poor OS, possibly influenced by factors such as age, transplanted organ, comorbidities, early death, and delayed diagnosis.
Keywords: Post-transplant lymphoproliferative disorder, Epstein-Barr virus, solid organ transplantation, hematopoietic stem cell transplantation.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
This work is licensed under a Creative Commons Attribution 4.0 International License.
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.
